Home > Insider Trading > Filing (0000950170-23-063121)

Filing Details

Accession Number:: 0000950170-23-063121
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-11-13 17:15:45
Reporting Period:: 2023-11-08

Accepted Time:: 2023-11-13 17:15:45
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1771917	Karuna Therapeutics Inc.	KRTX	Pharmaceutical Preparations (2834)	270605902

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1777631	K. Stephen Brannan	C/O Karuna Therapeutics, Inc. 99 High Street, 26Th Floor Boston MA 02110	Chief Medical Officer	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2023-11-08	2,500	$5.45	33,650	No	4	M	Direct
Common Stock	Acquisiton	2023-11-08	5,000	$131.64	38,650	No	4	M	Direct
Common Stock	Disposition	2023-11-08	1,281	$174.11	37,369	No	4	S	Direct
Common Stock	Disposition	2023-11-08	401	$175.69	36,968	No	4	S	Direct
Common Stock	Disposition	2023-11-08	265	$177.14	36,703	No	4	S	Direct
Common Stock	Disposition	2023-11-08	808	$178.90	35,895	No	4	S	Direct
Common Stock	Disposition	2023-11-08	2,245	$180.08	33,650	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Option (right to buy)	Disposition	2023-11-08	2,500	$0.00	2,500	$5.45
Common Stock	Option (right to buy)	Disposition	2023-11-08	5,000	$0.00	5,000	$131.64

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
14,677		2027-06-01	No	4	M	Direct
31,350		2031-02-22	No	4	M	Direct

Footnotes

The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2023.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $173.53 to $174.47, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) and (6) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $175.58 to $175.80, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $176.83 to $177.44, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $178.45 to $179.32, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $179.57 to $180.25, inclusive.
This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2017, with additional vesting as to 12.5% of the shares underlying the option award at the end of each six month period thereafter.
This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of February 23, 2021, with additional vesting as to 6.25% of the shares underlying the option award at the end of each three month period thereafter.